Table 3.
Results of Cox regression analysis for radiographic progression-free survival.
| Variables (Reference) | Univariable | Multivariable | ||
|---|---|---|---|---|
| HR (95% CI) | p | HR (95% CI) | p | |
| Age ≥ 65 years (<65 years) | 2.33 (0.98–5.55) | 0.055 | 1.63 (0.63–4.21) | 0.314 |
| Obesity (non-obesity) | 0.54 (0.23–1.26) | 0.155 | ||
| Sarcopenia (no sarcopenia) | 4.73 (1.40–15.96) | 0.012 | 3.77 (0.95–14.99) | 0.060 |
| SFI ≥ median (<median) | 0.65 (0.30–1.45) | 0.294 | ||
| VFI ≥ median (<median) | 0.97 (0.44–2.15) | 0.944 | ||
| VSR ≥ median (<median) | 0.90 (0.42–1.96) | 0.798 | ||
| PSA ≥ median (<median) | 1.11 (0.51–2.42) | 0.790 | 0.86 (0.33–2.24) | 0.759 |
| Abiraterone acetate (docetaxel) | 0.70 (0.28–1.79) | 0.463 | ||
| ECOG PS ≥ 1 (0) | 2.61 (1.12–6.07) | 0.026 | 2.27 (0.96–5.39) | 0.063 |
| Gleason score ≥ 8 (<8) | N/A | 0.963 | ||
| Stage cT4 (≤cT3) | 0.96 (0.41–2.22) | 0.918 | ||
| Regional LN metastasis (no) | 0.91 (0.34–2.44) | 0.853 | ||
| Bone metastasis (no) | 1.18 (0.44–3.14) | 0.748 | ||
| Visceral metastasis (no) | 0.97 (0.40–2.33) | 0.946 | ||
| High-volume (low-volume) | 2.15 (0.72–6.41) | 0.169 | 1.17 (0.21–6.53) | 0.855 |
| High-risk (low-risk) | 2.46 (0.73–8.30) | 0.147 | 0.89 (0.33–2.24) | 0.759 |
Variables with p < 0.10 in the univariable analysis are entered into the multivariable analysis, with age, baseline PSA level, disease volume, and disease risk being fixed.